scholarly journals Diagnostic value of cytologic investigation of cell count differential of pleural fluid

2007 ◽  
pp. 66-71
Author(s):  
O. G. Grigoruk ◽  
A. F. Lazarev ◽  
L. M. Bazulina

The cell count differential of pleural fluid sample is of great importance for estimation of the nature of pleural effusion. In the present article, we compared the efficiencies of routine cytology method with light microscopy, cytological examination with centrifuge Cytospin-4 and immunocytochemical methods. We have studied cytological samples from 1597 patients, with pleural effusion. Effusions associated with malignancies were reported in 22.7 % of patients including carcinomatosis (74.6 %), primary tumors of pleura (21.5 %), effusions associated with non epithelial malignancies (3.9 %). Benign pleural effusions were reactive (63.6 %), tuberculotic (13.5 %), "cholesterol pleurisy" and chylothorax (0.2 %). Carcinomatous pleuritis was found in patients with lung carcinoma (55.4 %), breast cancer (21.8 %) and ovary cancer (12.2 %). Specific malignant features (direct and indirect) were noted in pleural fluid on breast cancer, carcinomas of ovary, stomach, kidney, small cell lung carcinoma and squamous cell lung carcinoma. These features are hardly detected in patients with malignancies of intestines, prostate and endometria because these types of tumours are rarely metastatic to pleura. We were failed to define particular features of lung adenocarcinoma. The centrifuge Cytospin-4 was used in the most difficult cases (13.5 %) providing minimal number of presumable diagnosis. Primary tumours of pleura are the most difficult for detection. Immunocytochemical analysis found monoclonal mesothelial cell of НВЕМ 1 clone, cytokeratin, vimentin to be positive and carcinoembry onic antigen, Ber-EP4, CD-15 to be negative in the studied tumors.

2016 ◽  
Vol 140 (3) ◽  
pp. 662-673 ◽  
Author(s):  
Dennis Wang ◽  
Nhu-An Pham ◽  
Jiefei Tong ◽  
Shingo Sakashita ◽  
Ghassan Allo ◽  
...  

2015 ◽  
Vol 16 ◽  
pp. 912-915 ◽  
Author(s):  
Oluwaseyi D. Adejorin ◽  
Amik Sodhi ◽  
Felicia A. Hare ◽  
Arthur S. Headley ◽  
Luis C. Murillo ◽  
...  

2019 ◽  
Vol 40 (8) ◽  
pp. 808-814 ◽  
Author(s):  
Natale Quartuccio ◽  
Laura Evangelista ◽  
Pierpaolo Alongi ◽  
Federico Caobelli ◽  
Corinna Altini ◽  
...  

2021 ◽  
pp. 1-6
Author(s):  
Yaqian Wang ◽  
Seyedeh Maryam Seyed Barghi ◽  
Yanhong Yang ◽  
Reza Akhavan-Sigari

<b><i>Purpose:</i></b> In the current study, we tried to analyze the diagnostic value of HSP90α expression during the course of disease in patients treated with and without surgery. <b><i>Methods:</i></b> Three hundred and twelve patients with lung cancer who referred to Qinhuangdao First Hospital from June 2016 to March 2021 were selected as the experimental group and 160 healthy individuals subjected as the control group in this cohort study. The ELISA method was used to detect the expression level of plasma HSP90α. <b><i>Results:</i></b> We observed significant differences in the level of HSP90α in pathologic type, differentiation degree, stage, and presence of lung, liver, and bone metastasis; HSP90α was significantly higher in non-small cell lung carcinoma in comparison with small cell lung carcinoma, especially in lung adenocarcinoma. Our results demonstrated that HSP90α at 71.45 ng/mL had a sensitivity of 66.3% and a specificity of 95.0% for diagnosing lung cancer. Also, we observed that the HSP90α expression was significantly increased prior to lung cancer relapse in patients treated with chemoradiotherapy and surgery. <b><i>Conclusion:</i></b> Serum level of plasma HSP90α could be a reliable biomarker in diagnosing lung cancer and its subtypes and might be a valid biomarker for predicting lung cancer relapse in patients treated with chemoradiotherapy and surgery.


2011 ◽  
Vol 196 (5) ◽  
pp. 1176-1181 ◽  
Author(s):  
Davina Pawaroo ◽  
Natalie M. Cummings ◽  
Patrick Musonda ◽  
Robert C. Rintoul ◽  
Doris Rassl ◽  
...  

2021 ◽  
Vol 67 (10/2021) ◽  
Author(s):  
Bei Xie ◽  
Ying Wang ◽  
Jing Du ◽  
YanChun Li ◽  
Jianchao Wang ◽  
...  

CHEST Journal ◽  
1982 ◽  
Vol 81 (2) ◽  
pp. 208-211 ◽  
Author(s):  
Robert B. Livingston ◽  
Joseph D. McCracken ◽  
Christopher J. Trauth ◽  
Timothy Chen

2021 ◽  
Vol 27 ◽  
Author(s):  
Jing Qin ◽  
Fajun Xie ◽  
Chenghui Li ◽  
Na Han ◽  
Hongyang Lu

Purpose: The Myc family, especially C-MYC and MYCL1, has been found involved in small-cell lung carcinoma (SCLC). Identification of the frequency of C-MYC and MYCL1 expression among SCLC patients may help to identify potential targets for therapeutic intervention. Our aim was to detect MYCL1 amplification, L-Myc and c-Myc expression, and investigate clinicopathological characteristics and survival status in patients with surgically resected SCLC.Methods:MYCL1 amplification was detected using fluorescence in situ hybridization (FISH), while L-Myc and c-Myc protein expressions were determined using immunohistochemistry (IHC) in the primary tumors of 46 resected SCLC patients.Results: Among the 46 evaluated specimens, MYCL1 amplification was identified in 3/46 cases (6.5%). One of the positive cases was MYCL1 gene amplification combined with fusion. 3/46 (6.5%) was positive for L-myc protein expression, and 4/46 (8.7%) was positive for c-Myc protein expression.Conclusion: Our study firstly multidimensional explored the expression of MYCL1 amplification, L-Myc and c-Myc protein and investigated clinicopathological characteristics and survival status in patients with surgically resected SCLC, which makes a contribution to subsequent research and therapeutic strategies.


Sign in / Sign up

Export Citation Format

Share Document